Luminal (Her2 negative) prognostic index and survival of breast cancer patients. Cancer Epidemiol, 38, 286-90.Chen X, Cong Y, Pan L, et al. Luminal (Her2 negative) prognostic index and survival of breast cancer patients. Cancer Epidemiol. 2014;38(3): 286-290....
e13030#Background:IHC/FISH is currently the gold standard method of HER2 expression assessment on breast cancer (BC) cells. Recent studies regarding HER2-low category show that the semi-quantitative methods are inaccurate. False-negative results may have a negative impact on the prognosis and ...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Gallen International Breast Cancer Conference for early breast cancer [4], individual molecular markers divided breast cancer into five subtypes. In general, the subtypes luminal A or luminal B (HER2 negative or HER2 positive), basal like or HER2 positive subtypes can be differentiated by the ...
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and repo...
摘要: We suggest that Nectin-4 is a relevant prognostic factor and a therapeutic target in luminalB (HER2 negative) breast cancer.关键词:Breast cancer Nectin-4 St. Gallen Luminal B Overall survival DOI: 10.1016/j.prp.2017.07.019 被引量: 4 ...
Triple-negative breast cancer (TNBC) is the subtype of breast cancer that does not express the estrogen receptor or progesterone receptor and does not overexpress human epidermal growth factor 2. Of all breast cancer subtypes, it carries the worst prognosis and has limited treatment options. Metabol...
3、Yoder, Rachel et al. “Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.” NPJ breast cancer vol. 8,1 80. 11 ...
Triple negative breast cancer (TNBC) is one of the most aggressive form of breast cancer. It is characterized by the absence of estrogen, progesterone and human epidermal growth factor receptors. The main issue with TNBC is that it exhibits poor prognosis, high risk of relapse, sh...
About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low ca